{"id":11509,"date":"2024-05-21T07:00:00","date_gmt":"2024-05-21T05:00:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-pa-abgsc-investor-days\/"},"modified":"2024-05-21T07:00:00","modified_gmt":"2024-05-21T05:00:00","slug":"irlab-presenterar-pa-abgsc-investor-days","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-abgsc-investor-days\/","title":{"rendered":"IRLAB presenterar p\u00e5 ABGSC Investor Days"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>G\u00f6teborg den 21 maj, 2024 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett f\u00f6retag som uppt\u00e4cker och utvecklar nya behandlingar f\u00f6r Parkinsons sjukdom, meddelade idag att bolaget kommer att presentera p\u00e5 ABGSC Investor Days i Stockholm torsdagen den 23 maj.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>IRLAB representeras av Gunnar Olsson, vd, som kommer att h\u00e5lla en 30-minuterspresentation inklusive Q&amp;A kl. 10.45-11.15. Evenemanget h\u00e5lls p\u00e5 Hotel At Six, Brunkebergstorg 6 i Stockholm.<\/p>\n<p>Mer information kan hittas p\u00e5 eventets hemsida: <a href=\"https:\/\/cr.abgsc.com\/artiklar\/2024\/april\/abgsc-investor-days-22-23-may\/\" rel=\"noopener\" target=\"_blank\">https:\/\/cr.abgsc.com\/artiklar\/2024\/april\/abgsc-investor-days-22-23-may\/<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-3931160317df\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information:<\/strong><\/p>\n<hr \/>\n<p>Gunnar Olsson, VD<br \/>Telefon: +46 70 576 14 02<br \/>E-mail:\u00a0<a href=\"mailto:gunnar.olsson@irlab.se\" rel=\"noopener\" target=\"_blank\">gunnar.olsson@irlab.se<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-a19a8f82b785\">\n<p><strong class=\"mfn-heading-1\">Om IRLAB<\/strong><\/p>\n<hr \/>\n<p>IRLAB uppt\u00e4cker och utvecklar en portf\u00f6lj av transformativa behandlingar f\u00f6r alla stadier av Parkinsons sjukdom. Bolaget har sitt ursprung i Nobelpristagaren Prof. Arvid Carlssons forskargrupp och uppt\u00e4ckten av ett samband mellan hj\u00e4rnans signalsubstanser och CNS-st\u00f6rningar. Mesdopetam (IRL790), under utveckling f\u00f6r behandling av levodopa-inducerade dyskinesier, har slutf\u00f6rt Fas IIb och \u00e4r i f\u00f6rberedelse f\u00f6r Fas III. Pirepemat (IRL752), befinner sig f\u00f6r n\u00e4rvarande i Fas IIb, och utv\u00e4rderas f\u00f6r sin effekt p\u00e5 balans och fallfrekvens vid Parkinson. Dessutom utvecklar bolaget \u00e4ven de tre prekliniska programmen IRL757 (med finansiering fr\u00e5n Michael J. Fox Foundation), IRL942 och IRL1117 mot Fas I-studier. IRLAB:s pipeline har genererats av bolagets egenutvecklade systembiologibaserade forskningsplattform Integrative Screening Process (ISP). IRLAB har sitt huvudkontor i Sverige och \u00e4r noterat p\u00e5 Nasdaq Stockholm (IRLAB A). F\u00f6r mer information, bes\u00f6k\u00a0<a href=\"http:\/\/www.irlab.se\/\" rel=\"noopener\" target=\"_blank\">www.irlab.se<\/a>.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/53c6d1e8-e8d7-4dc3-b8e5-07e204690c27\/irlab-presenterar-pa-abgsc-investor-days.pdf\" rel=\"noopener\" target=\"_blank\">IRLAB presenterar p\u00e5 ABGSC Investor Days<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>G\u00f6teborg den 21 maj, 2024 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett f\u00f6retag som uppt\u00e4cker och utvecklar nya behandlingar f\u00f6r Parkinsons sjukdom, meddelade idag att bolaget kommer att presentera p\u00e5 ABGSC Investor Days i Stockholm torsdagen den 23 maj.<\/p>\n","protected":false},"template":"","class_list":["post-11509","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>IRLAB presenterar p\u00e5 ABGSC Investor Days - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-abgsc-investor-days\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB presenterar p\u00e5 ABGSC Investor Days - IRLAB\" \/>\n<meta property=\"og:description\" content=\"G\u00f6teborg den 21 maj, 2024 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett f\u00f6retag som uppt\u00e4cker och utvecklar nya behandlingar f\u00f6r Parkinsons sjukdom, meddelade idag att bolaget kommer att presentera p\u00e5 ABGSC Investor Days i Stockholm torsdagen den 23 maj.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-abgsc-investor-days\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-abgsc-investor-days\/\",\"url\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-abgsc-investor-days\/\",\"name\":\"IRLAB presenterar p\u00e5 ABGSC Investor Days - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2024-05-21T05:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-abgsc-investor-days\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-abgsc-investor-days\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-abgsc-investor-days\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IRLAB presenterar p\u00e5 ABGSC Investor Days\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson&#039;s disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB presenterar p\u00e5 ABGSC Investor Days - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-abgsc-investor-days\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB presenterar p\u00e5 ABGSC Investor Days - IRLAB","og_description":"G\u00f6teborg den 21 maj, 2024 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett f\u00f6retag som uppt\u00e4cker och utvecklar nya behandlingar f\u00f6r Parkinsons sjukdom, meddelade idag att bolaget kommer att presentera p\u00e5 ABGSC Investor Days i Stockholm torsdagen den 23 maj.","og_url":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-abgsc-investor-days\/","og_site_name":"IRLAB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-abgsc-investor-days\/","url":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-abgsc-investor-days\/","name":"IRLAB presenterar p\u00e5 ABGSC Investor Days - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2024-05-21T05:00:00+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-abgsc-investor-days\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-abgsc-investor-days\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-abgsc-investor-days\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"IRLAB presenterar p\u00e5 ABGSC Investor Days"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson&#039;s disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/11509","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=11509"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}